Twelve patients with 16 leg ulcers, existing for at least 3 months and not responsive to conventional inpatient therapy of at least 3 weeks, were treated with repeated applications of cultured allogenic keratinocyte sheets. A marked decrease in size was seen in all ulcers but 2. Complete closure of the ulcer was seen in 62% of the ulcers within 8 weeks. Healing was due to enhanced granulation and increased epithelialization, starting from the periphery of the wound. This edge effect suggests that the epidermal allografts act by stimulation of migration and/or multiplication of the acceptor's keratinocytes, rather than by take of the allograft.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000247628 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in preparation of acellular human dermis for tissue banking and transplantation.
Cell Tissue Bank
December 2024
NHS Blood and Transplant, Tissue Services R&D, 14 Estuary Banks, Speke, Liverpool, L24 8RB, UK.
Article Synopsis
- Non-healing wounds lead to significant costs for the NHS, totaling over £5.6 billion annually, prompting the use of skin allografts for better infection protection.
- A study aimed to validate a new decellularisation method using Benzonase, a single enzyme, to remove DNA from donor skin, which could simplify the process compared to the current dual-enzyme approach.
- Results showed that both Benzonase and the existing method effectively removed DNA without significant differences in their performance, demonstrating Benzonase's non-toxicity and potential as a cost-effective alternative in wound treatment.
Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in renal allografts: A series of 6 patients.
Am J Transplant
November 2024
Arkana Laboratories, Little Rock, Arkansas, USA. Electronic address:
Membranous nephropathy (MN) is a major cause of nephrotic syndrome, and neural epidermal growth factor-like 1 protein (NELL1) is the second most common inciting antigen. An increasing number of exposures and diseases have been associated with NELL1 MN. There are limited data on NELL1 following kidney transplantation with only 1 previously reported case.
View Article and Find Full Text PDFLangerhans Cell Histiocytosis or Acute Cellular Rejection?
Pediatr Transplant
December 2024
Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Background: Langerhans cell histiocytosis (LCH) is a rare malignant disorder of epidermal antigen presenting cells. It is characterized by infiltration of various tissues with dendritic cells (Langerhans cells, LC) that express CD1a or CD207 (langerin), often leading to organ dysfunction. A patient with LCH required liver transplantation (LT) for LCH-associated biliary-tract disease.
View Article and Find Full Text PDFFrom Bank Preparation to Clinical Use of Homologous Skin Allografts in Wound Healing: A Sustainable Approach.
Life (Basel)
October 2024
Skin Bank Unit, Azienda Ospedaliera Universitaria Senese (AOUS), 53100 Siena, Italy.
Given progressive population ageing and the increase in the number of patients with comorbidities, the management of chronic and/or hard-to-heal wounds (HHWs) nowadays represents a common problem in many clinical settings. In these cases, standard strategies may not be sufficient. Autologous grafting represent the gold standard for permanent wound closure, but is almost never realized when the skin loss is extensive/the patient is young.
View Article and Find Full Text PDFEnhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.
Cancer Immunol Immunother
October 2024
School of Pharmacy, Shanghai Jiao Tong University, No.800, Dongchuan Rd, Shanghai, 200240, People's Republic of China.
Article Synopsis
- Tumor-reactive T cells are essential for fighting tumors, but traditional DNA vaccines are slow and not very effective, prompting the study of an electroporation-mediated vaccine targeting a specific tumor variant (pEGFRvIII) combined with adoptive cell therapy (ACT).
- The research involved testing the effectiveness of the pEGFRvIII vaccine in mice using various methods like immunofluorescence, flow cytometry, and cytotoxicity assays to assess T cell responses and tumor growth inhibition.
- Results showed that while the vaccine alone had limited impact on tumor growth, pairing it with ACT from healthy donors produced a strong anti-tumor response, highlighting the potential of this combination approach for treating tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!